Longitudinal clinical trial enrollment trends across 341 US FDA-approved drugs and their guiding role in precision medicine strategies
Persistent imbalances in trial enrollment limit the delivery of precision medicine. Trial location and regulatory designations influence who is included. Earlier planning of trials and more strategic site selection improve the potential for future treatments to serve individuals from all racial and ethnic groups.
Authors
- Sophie Zaaijer (ORCID: https://orcid.org/0000-0002-0437-8620)
- Simon C. Groen (ORCID: https://orcid.org/0000-0003-4538-8865)
Institutions
- University of California, Riverside (US)
- University of California, Irvine (US)
- Cornell University (US)
Publication Details
- Journal
- Communications Medicine
- Published
- 2025-12-05
- DOI
- https://doi.org/10.1038/s43856-025-01270-2
- Primary Topic
- Statistical Methods in Clinical Trials
- Type
- article
- Field-Weighted Citation Impact
- 0.00